IL-17 Inhibitor Deal Benchmarks

IL-17 inhibitors have become the gold standard for plaque psoriasis treatment, with secukinumab, ixekizumab, and bimekizumab generating $10B+ in combined annual revenue. Phase 2 IL-17 inhibitor deals carry a median total deal value of $2.1B, with upfront payments of $400M. The validated pathway, large addressable population (7.5M US psoriasis patients), and expanding indication potential (psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa) sustain robust deal activity.

Milestone structures for IL-17 inhibitor deals allocate $350M to development milestones, $437M to regulatory milestones, and $961M to commercial milestones. The 19/81 upfront/milestone split reflects the well-defined clinical development pathway with PASI 75/90/100 as established primary endpoints.

Royalty rates for IL-17 inhibitor licensing range from 6.6% to 13.1% at the base tier. Differentiation factors include IL-17A versus IL-17A/F versus IL-17C selectivity, dosing frequency, immunogenicity profile, and potential for combination with other pathways. Next-generation IL-17 inhibitors with oral bioavailability or improved convenience (fewer injections, auto-injector delivery) command the highest premiums.